MannKind
Manufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
30930 Russell Ranch Rd Ste 300, Westlake...Phone Number
(818) 661-5000Website
www.mannkindcorp.comRevenue
$360.8 MillionStock Symbol
MNKDIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
7
1
1
1
2
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension.Explore more
MannKind Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MannKind your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if MannKind had a recent Job posting/layoffs
Check out if MannKind is spiking on competitors!
Funding: Get notified immidiatlly once MannKind has new funding data
Check if MannKind has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when MannKind launches new products
Congratulate Masked Content for being promoted to Masked Content at MannKind
Earning: See what the market has to say on MannKind recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MannKind, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at MannKind
Find 2 more new buyers
Compare Similar Companies to MannKind
Compare insights from companies similar to MannKind, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MannKind is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MannKind is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MannKind.
MannKind financials insights
Gather financial insights about MannKind, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Corporate Investment
$150M
2015
Stock Offering
$36.2M
2016
Stock Offering
$47.5M
2017
Stock Offering
$61M
2018
Stock Offering
$28M
2020
Debt
$2M
2025
Stock/Share Issuance
$500M
MannKind Tech Stack
A closer look at the technologies used by MannKind
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Hiring Plans
MannKind has more open roles in Marketing than it has had at any time in the past 12 months. Areas of expertise include: Brand Awareness, Market Access Strategy, Marketing Planning, Market Research, Sales Support, Competitive Analysis, and Marketing Budgets.
Hiring Plans
Open Position
MannKind News & Media
ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly
At the American Diabetes Association (ADA) conference 2026, Roche, Lilly and others presented data.Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID UseMannKind (MNKD) Advances Clinical Trials for Inhaled IPF Therapy
MannKind Corporation (NASDAQ:MNKD) is one of the most promising penny stocks according to Wall Street analysts. On June 3, MannKind reached key milestones in its clinical program for nintedanib DPI, a dry powder inhalation therapy for idiopathic pulmonary fibrosis/IPF. The company has completed patient randomization for its US Phase 1b INFLO-1 trial and successfully enrolled […]MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MannKind
Sign Up For FreeTo access detailed company insights
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery dev... Read More
